ABT-354
ABT-354 is a pharmaceutical compound that has been investigated for its potential therapeutic effects in the treatment of Alzheimer's disease and other neurodegenerative disorders. It is a selective inhibitor of the beta-secretase enzyme, which plays a crucial role in the formation of amyloid-beta peptides. These peptides aggregate to form plaques, a hallmark of Alzheimer's pathology.
Mechanism of Action[edit | edit source]
ABT-354 functions by inhibiting the activity of beta-secretase, also known as BACE1. This enzyme is responsible for the cleavage of the amyloid precursor protein (APP) into amyloid-beta peptides. By inhibiting BACE1, ABT-354 reduces the production of amyloid-beta, thereby potentially slowing the progression of Alzheimer's disease.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of ABT-354 includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to cross the blood-brain barrier effectively, ensuring adequate concentrations in the central nervous system. The metabolism of ABT-354 primarily occurs in the liver, and it is excreted through renal and fecal pathways.
Clinical Trials[edit | edit source]
ABT-354 has undergone several phases of clinical trials to evaluate its safety, efficacy, and tolerability in patients with Alzheimer's disease. Early-phase trials focused on determining the optimal dosing regimen and assessing any adverse effects. Later-phase trials aimed to establish the drug's efficacy in reducing cognitive decline and improving quality of life for patients.
Adverse Effects[edit | edit source]
Common adverse effects observed in clinical trials of ABT-354 include headache, dizziness, and gastrointestinal disturbances. Serious adverse effects are rare but may include liver enzyme elevations and hypersensitivity reactions.
Research and Development[edit | edit source]
The development of ABT-354 is part of a broader effort to find disease-modifying treatments for Alzheimer's disease. Research continues to explore its long-term effects and potential benefits in combination with other therapeutic agents.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
